• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2021 Fiscal Year Final Research Report

Novel immunoradiation strategy based on autologous T cells derived exosome

Research Project

  • PDF
Project/Area Number 20K16825
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 52040:Radiological sciences-related
Research InstitutionKobe University

Principal Investigator

Hikaru Kubota  神戸大学, 医学部附属病院, 医員 (60824208)

Project Period (FY) 2020-04-01 – 2022-03-31
Keywords放射線治療 / 免疫チェックポイント阻害剤 / 免疫放射線治療 / エクソソーム
Outline of Final Research Achievements

We have established a method for isolating exosomes in vivo. Next, CD8-positive T cells were isolated from the spleen of mice, and it was confirmed that the exosome marker CD9 was expressed in the culture supernatant. In addition, CD8-positive T cell-derived exosomes were extracted and confirmed that PD-1 was expressed. In terms of the affinity of PD-1 / PD-L, it was suggested that administration of PD-1 expressing autologous-exosomes may be more effective than conventional immune checkpoint inhibitors . Finally, it was confirmed that CD47 was expressed in exosomes derived from CD8-positive T cells. CD47 expression may avoid macrophage phagocytosisin vivo.

Free Research Field

放射線治療

Academic Significance and Societal Importance of the Research Achievements

本研究の成果は自己血T細胞由来エクソソームを用いた新規免疫放射線治療戦略を前進させるものである。我々はCD8陽性T細胞から放出されるエクソソームを抽出し、その膜上にPD-1が発現している事を確認した。CD8陽性T細胞由来のエクソソーム膜解析の中で、CD47発現が確認された。CD47は所謂「don’t eat me signal」である。通常であればエクソソームは網内系で貪食されるが、それを回避することが可能であることを示唆している。自己血T細胞由来のエクソソームが免疫チェックポイント阻害剤を代替できることを示すことができれば、その社会的意義は計り知れない。

URL: 

Published: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi